HLB Therapeutics Co.,Ltd.
115450
Rankning i aktier
#18263
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Aktiekurs
$2.02
Marknadsvärde
$190.66M
Förändring (1 dag)
7.96%
Förändring (1 år)
-1.16%
Land
KR
Handel HLB Therapeutics Co.,Ltd. (115450)
Kategori
Healthcare
Vinst för HLB Therapeutics Co.,Ltd. (115450)
Vinst i 2026 TTM: 0
Enligt de senaste finansiella rapporterna från HLB Therapeutics Co.,Ltd. är företagets nuvarande vinst 0. År 2026 hade företaget en vinst på 0, lika med vinsten år 2026 som var 0. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för HLB Therapeutics Co.,Ltd. från 2016 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2025 | $-7.67M | -50.79% |
| 2024 | $-15.59M | 628.99% |
| 2023 | $-2.14M | -79.94% |
| 2022 | $-10.66M | -26.90% |
| 2021 | $-14.59M | -3.96% |
| 2020 | $-15.19M | 13.78% |
| 2019 | $-13.35M | -384.01% |
| 2018 | $4.70M | -196.15% |
| 2017 | $-4.89M | 9.69% |
| 2016 | $-4.46M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
